Platinum deficit beckons in second half as ETF selling eases
A projected platinum supply deficit implies tighter availability of platinum metal in the second half.
Source →The trace
How it reaches your house.
Starting from Platinum group metal (pharmaceutical grade), we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
Palladium and platinum group metals →Shortage riskMarket Delivery
A projected swing back into platinum deficit means less metal is available to reach the market-delivery stage in the second half.
95% confidencePlatinum Group Metals (PGMs) — Catalytic Converters →Prices riseA tighter platinum market raises PGM catalyst costs for this critical downstream auto-parts and repairs use.
89% confidencePlatinum Group Metals (PGMs) — Catalytic Converters →Stands to benefitAs the source of 72% of supply, South Africa's PGM mining and export earnings should benefit most from a tighter platinum market.
84% confidenceHop 2
Cancer and specialty drugs →Shortage riskPlatinum group metal (pharmaceutical grade)
A projected platinum deficit directly tightens the pharmaceutical-grade platinum feedstock used by cancer and specialty drugs.
97% confidenceSouth Africa →Shortage riskPlatinum Group Metals (PGMs) — Catalytic Converters
South Africa accounts for 72% of this input, so a South African platinum supply deficit should materially tighten PGM availability for catalytic converters.
90% confidenceSouth Africa →Shortage riskHop 3
PGM Sulfide Ore — Bushveld Complex (South Africa) →Shortage riskPalladium and platinum group metals
This edge is marked critical with dependency_strength 0.95, so a squeeze at the Bushveld ore node should transmit almost directly into tighter PGM availability.
92% confidenceCisplatin / carboplatin API →Shortage riskA platinum-driven squeeze on cisplatin/carboplatin API would directly tighten supply of this critical downstream therapy category.
91% confidenceGeneric Oncology Injectable Vials (Cisplatin, Carboplatin, Paclitaxel) →Shortage riskHop 4
Hikma Pharmaceuticals PLC →Shortage riskGeneric Oncology Injectable Vials (Cisplatin, Carboplatin, Paclitaxel)
Platinum metal shortages directly tighten supply for platinum-based oncology injectables such as cisplatin and carboplatin, which Hikma uses in this input line.
83% confidencePfizer (Hospira) →Shortage riskGeneric Oncology Injectable Vials (Cisplatin, Carboplatin, Paclitaxel)
Pfizer/Hospira’s generic oncology injectable line is the platinum-linked product in the chain, so a tighter platinum market should reduce availability of these injectables.
81% confidenceFresenius Kabi AG →Shortage risk
Where it lands
What you buy, and what you own.
Goods you buy
Auto parts and repairs · Vehicles and light trucks · Cancer and specialty drugs · Palladium and platinum group metals
In the MyPRIA app, this is checked against your own holdings.